Brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post sales of $400,000.00 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $410,000.00 and the lowest estimate coming in at $400,000.00. The firm is expected to report its next earnings report on Monday, March 11th.

On average, analysts expect that Syros Pharmaceuticals will report full year sales of $1.58 million for the current financial year, with estimates ranging from $1.56 million to $1.60 million. For the next financial year, analysts forecast that the company will post sales of $1.94 million, with estimates ranging from $1.60 million to $2.50 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The firm had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.

Several research analysts have recently commented on the company. HC Wainwright reiterated a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, August 8th. BidaskClub upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 31st. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Friday, August 10th. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. Finally, Roth Capital upgraded shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Monday, November 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $19.29.

Several institutional investors and hedge funds have recently bought and sold shares of SYRS. Acadian Asset Management LLC increased its stake in Syros Pharmaceuticals by 7,084.0% during the second quarter. Acadian Asset Management LLC now owns 28,233 shares of the company’s stock valued at $288,000 after purchasing an additional 27,840 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $611,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Syros Pharmaceuticals by 79.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,661 shares of the company’s stock worth $1,048,000 after purchasing an additional 45,350 shares during the period. Alps Advisors Inc. bought a new stake in shares of Syros Pharmaceuticals in the second quarter valued at approximately $483,000. Finally, Rhumbline Advisers raised its stake in shares of Syros Pharmaceuticals by 87.6% in the second quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after purchasing an additional 10,494 shares in the last quarter. Institutional investors own 61.26% of the company’s stock.

Shares of SYRS traded down $0.51 during trading hours on Friday, hitting $7.00. The company had a trading volume of 150,607 shares, compared to its average volume of 84,765. The company has a market cap of $229.19 million, a P/E ratio of -3.29 and a beta of 0.80. Syros Pharmaceuticals has a 52-week low of $6.25 and a 52-week high of $14.90.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Story: Day Trading – Risk Worth the Reward?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.